Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Vein Ablation Versus Amiodarone in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 65 years at moment of screening, able to sign informed consent.~* Documented paroxysmal AF in association with complaints in the last year, with at least 2 episodes of complaints attributed to AF in the previous 2 months.~* Paroxysmal AF documented with at least one ECG with sinus rhythm not after cardioversion in the last year.~* No prior use of amiodarone in the last 6 months and no usage longer than 4 weeks in total.~Exclusion Criteria:~* EF \< 35 % or description of poor left ventricular function on echocardiogram. Measurement should not be older than 6 months at moment of screening.~* Aortic, mitral, pulmonary or tricuspid valve regurgitation or stenosis, if graded severe (grade \>3)~* Acute illness: unstable angina, infectious disease.~* Primary structural or electrical heart disease: dilated cardiomyopathy, hypertrophic cardiomyopathy, Brugada syndrome, long QT syndrome.~* Reversible causes (thyroid dysfunction, uncontrolled hypertension, ischemia).~* Previous ablation.~* Contraindications for amiodarone; liver dysfunction (serum alanine aminotransferase \>2.5 times upper limit); thyroid dysfunction; chronic lung disease; baseline QTc \>460 ms. sinus node dysfunction (pause more than 3 seconds in sinus rhythm); second or third degree AV-block.~* Contraindications for anti-coagulation: prior life threatening hemorrhage under use of Vitamin K antagonists.~* Any myocardial infarction or PCI in previous 6 months.~* CABG in previous 6 months.~* Renal dysfunction: creatinine clearance \<45 ml/min~* Severe co-morbidity. Life expectancy less than 1 year.~* Thrombus in left atrium~* Untreatable allergy to contrast media

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PVI ablation (Type: EXPERIMENTAL): Pulmonary Vein Ablation
- Amiodarone medical treatment (Type: ACTIVE_COMPARATOR): Amiodarone medical treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).